Galapagos: positive data in psoriatic arthritis
(CercleFinance.com) - Gilead Sciences and Galapagos have announced new positive analyses on both the Phase II clinical trials Equator and Equator-2, evaluating their investigational drug filgotinib in adults suffering from psoriatic arthritis (PsA).
This data demonstrated the sustained efficacy and consistent safety profile of the product in patients with active PsA, and illustrated rapid and sustained reductions in inflammatory biomarkers in patients with moderate-to-severe PsA.
Both pharmaceutical groups, which are collaborating on the development and commercialisation of filgotinib, said that this data was presented at the 2020 European Congress of Rheumatology.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This data demonstrated the sustained efficacy and consistent safety profile of the product in patients with active PsA, and illustrated rapid and sustained reductions in inflammatory biomarkers in patients with moderate-to-severe PsA.
Both pharmaceutical groups, which are collaborating on the development and commercialisation of filgotinib, said that this data was presented at the 2020 European Congress of Rheumatology.
Copyright (c) 2020 CercleFinance.com. All rights reserved.